Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 21:11:612304.
doi: 10.3389/fneur.2020.612304. eCollection 2020.

Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel

Livnat Brill  1 , Esther Ganelin-Cohen  2 , Ron Dabby  3 , Shira Rabinowicz  4 , Efrat Zohar-Dayan  4 , Netaniel Rein  1 , Eyal Aloni  5 , Yuval Karmon  6 , Adi Vaknin-Dembinsky  1
Affiliations

Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel

Livnat Brill et al. Front Neurol. .

Abstract

Introduction: Myelin oligodendrocyte glycoprotein (MOG) antibody associated disorders (MOGAD) have been recognized over the past 10 years as distinct inflammatory, demyelinating diseases of the central nervous system (CNS). Antibodies against MOG are found mostly in patients with optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and aquaporin-4 antibody (AQP4-abs)-seronegative neuromyelitis optica spectrum disorders (NMOSD). However, data on the disease course and disability outcomes of these patients are scarce. Aim: To describe clinical and paraclinical features associated with MOG antibodies (abs) in a cohort of patients in Israel, and to assess baseline prognostic features of MOG-ab-associated diseases after a first acute demyelinating event. Methods: MOG-abs were identified in serum using a cell-based assay, and clinical data were collected from the patients' medical records. Results: Of 683 patients with demyelinating diseases tested for MOG-abs, 53 were positive (7.7%), with ON the most common presenting phenotype (68%). The age range of MOG-abs seropositive patients was 1-66 years, with increased prevalence in children (19% compared to 6.7% in adults) (p < 0.01). The highest prevalence of seropositivity was observed in children aged younger than 10 years (25.5%), followed by those aged 31-40 years (16.6%). Conclusions: MOGAD are distinct autoimmune diseases that occurs at all stages of life with a significantly higher prevalence in children; the main clinical presenting phenotype in the entire cohort is ON and young children most often presented with ON or ADEM. Our data highlight the need for repeated evaluation of MOG-abs in patients with acquired CNS demyelinating disorders, especially in children under 10 and adults between 31 and 40 years of age.

Keywords: ADEM; MOG antibody disease (MOGAD); MOG-IgG; MS; NMOSD; demyelinating diseases; encephalitis; optic neuritis (ON).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Age at onset in MOG-abs-positive patients in Israel. % of MOG-abs-seropositive patients of those patients with demyelinating disease tested for MOG-abs.
Figure 2
Figure 2
The seroprevalence of MOG-abs is age-dependent. The mean percentages of MOG-abs-positive patients are shown for each subpopulation.
Figure 3
Figure 3
Distribution of seropositive MOG-abs among pediatric and adults clinical phenotype.
See this image and copyright information in PMC

References

    1. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinfl. (2016) 13:279. 10.1186/s12974-016-0717-1 - DOI - PMC - PubMed
    1. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. (2012) 79:1273–7. 10.1212/WNL.0b013e31826aac4e - DOI - PubMed
    1. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. (2013) 9:455–61. 10.1038/nrneurol.2013.118 - DOI - PubMed
    1. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. (2019) 15:89–102. 10.1038/s41582-018-0112-x - DOI - PubMed
    1. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. (1999) 72:1–9. 10.1046/j.1471-4159.1999.0720001.x - DOI - PubMed

LinkOut - more resources